pteridines has been researched along with Itching in 1 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "BI 2536 is a potent, highly selective inhibitor of polo-like kinase (Plk) 1." | 2.78 | A phase I open-label dose-escalation study of intravenous BI 2536 together with pemetrexed in previously treated patients with non-small-cell lung cancer. ( Chu, QS; Ellis, PM; Fritsch, H; Gaschler-Markefski, B; Gyorffy, S; Laurie, SA; Leighl, N; Munzert, G, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ellis, PM | 1 |
| Chu, QS | 1 |
| Leighl, N | 1 |
| Laurie, SA | 1 |
| Fritsch, H | 1 |
| Gaschler-Markefski, B | 1 |
| Gyorffy, S | 1 |
| Munzert, G | 1 |
1 trial available for pteridines and Itching
| Article | Year |
|---|---|
A phase I open-label dose-escalation study of intravenous BI 2536 together with pemetrexed in previously treated patients with non-small-cell lung cancer.
Topics: Administration, Intravenous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, | 2013 |